
Daiichi Sankyo and Puma Biotech to assess combination cancer therapy
The firms will explore Daiichi Sankyo’s DS-8201, an investigational antibody-drug conjugate (ADC), in conjunction with Puma Biotechnology’s pan-HER tyrosine kinase inhibitor called neratinib (Nerlynx). DS-8201 is being developed as a smart chemotherapy and contains a […]